Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient
Harcourt, J.; Tamin, A.; Lu, X.; Kamili, S.; Kumar Sakthivel, S.; Wang, L.; Murray, J.; Queen, K.; Lynch, B.; Whitaker, B.; Tao, Y.; Paden, C.; Zhang, J.; Li, Y.; Uehara, A.; Wang, H.; Goldsmith, C.; Bullock, H.; Gautam, R.; Schindewolf, C.; Lokugamage, K. G.; Scharton, D.; Plante, J.; Mirchandani, D.; Widen, S.; Narayanan, K.; Makino, S.; Ksiazek, T.; Plante, K. S.; Weaver, S.; Menachery, V. D.; Thornburg, N. J.
Show abstract
The etiologic agent of the outbreak of pneumonia in Wuhan China was identified as severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) in January, 2020. The first US patient was diagnosed by the State of Washington and the US Centers for Disease Control and Prevention on January 20, 2020. We isolated virus from nasopharyngeal and oropharyngeal specimens, and characterized the viral sequence, replication properties, and cell culture tropism. We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin. We also deposited the virus into two virus repositories, making it broadly available to the public health and research communities. We hope that open access to this important reagent will expedite development of medical countermeasures. Article SummaryScientists have isolated virus from the first US COVID-19 patient. The isolation and reagents described here will serve as the US reference strain used in research, drug discovery and vaccine testing.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 B.1.1.7 infection of Syrian hamster does not cause more severe disease and is protected by naturally acquired immunity 96%
- Gemykibivirus detection in acute encephalitis patients from Nepal 95%
- Sustained replication of synthetic canine distemper virus defective genomes in vitro and in vivo 95%
Similar papers in this journal
- Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity 96%
- SARS-CoV-2 variants from long-term, persistently infected immunocompromised patients have altered syncytia formation, temperature-dependent replication, and serum neutralizing antibody escape 95%
- Propagation, inactivation, and safety testing of SARS-CoV-2 95%
Similar papers in this journal
- Rescue of SARS-CoV-2 from a single bacterial artificial chromosome 97%
- Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating 96%
- Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas 96%
Similar papers in this journal
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 97%
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants 95%
- A Short Plus Long-Amplicon Based Sequencing Approach Improves Genomic Coverage and Variant Detection In the SARS-CoV-2 Genome 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.